Alliance Pharma Regulatory News (APH)

8 Jun 2006 07:01

Alliance Pharma PLC08 June 2006 For Immediate Release 8 June 2006 ALLIANCE PHARMA PLC ("Alliance Pharma" or "the Company") Appointment of Non-Executive Director Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleasedto announce that it has appointed Andrew Leonard Smith, a highly experiencedhealthcare executive, as a Non-Executive Director of the Company. Mr Smith, aged 56, has international experience of the pharmaceutical,biotechnology and medico-marketing services industries gained at companiesincluding SmithKline Beecham plc, Cerebrus plc and Parexel International. He iscurrently a consultant with the partnership Navitas BioPharma Consulting, whichfocuses on small to medium sized companies in biotechnology and pharmaceuticals. Between 1987 and 1996, Mr Smith worked in a number of marketing and managerialroles at SmithKline Beecham (now GlaxoSmithKline plc) including ManagingDirector and Senior Vice President of SmithKline Beecham Pharmaceuticals UK &Ireland and Chairman of Diversified Health Systems Europe. Mr Smith was Chief Executive Officer of UK biotechnology company Cerebrus plcbetween 1996 and 1999 and, after Cerebrus was acquired by Vanguard Medica plc(now Vernalis plc) he moved to Boston, MA, to take the position of President ofParexel International's Medical Marketing Services Business. Michael Gatenby, Alliance Pharma's Chairman, said: "I am delighted to welcomeAndrew to Alliance Pharma's Board. His considerable experience gained across thepharmaceutical industry will be of significant value to the Company in itsfuture development, particularly in the commercialisation of our keydevelopments of Posidorm and Isprelor." Directorships held by Andrew Smith in the past five years: Rosemont Pharmaceuticals LtdParexel International Corp Inc There are no further disclosures to be made in accordance with Schedule 2 (g) ofthe AIM rules. For further information: Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief ExecutiveMaddy Scott, Finance Directorwww.alliancepharma.co.uk Buchanan Communications + 44 (0) 20 7466 5000Mark Court/Lisa Baderoon/Rebecca Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceuticalcompany based in Chippenham, Wiltshire, UK. The company has a strong trackrecord of acquiring the rights to established niche brands and owns, or shares,the rights to 30 branded pharmaceutical products and continues to exploreopportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to UK and International pharmaceuticalwholesalers which service both hospital and retail pharmacies with theirprescription requirements. Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor forthe induction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. -------------------------- This information is provided by RNS The company news service from the London Stock Exchange